Characteristics of patients with Crimean-Congo hemorrhagic fever in a recent outbreak in Turkey and impact of oral ribavirin therapy
about
Ribavirin for Crimean-Congo hemorrhagic fever: systematic review and meta-analysisCrimean-Congo hemorrhagic fever (CCHF) in Southern KordofanCrimean-Congo Hemorrhagic FeverCan non-human primates serve as models for investigating dengue disease pathogenesis?Crimean-Congo haemorrhagic fever in Kosova : a fatal case reportDiagnostics in Ebola Virus Disease in Resource-Rich and Resource-Limited SettingsRibavirin for patients with Crimean-Congo haemorrhagic fever: a systematic review and meta-analysisImported Crimean-Congo hemorrhagic fever cases in IstanbulCrimean-Congo haemorrhagic fever among children in north-eastern Turkey.Climate, niche, ticks, and models: what they are and how we should interpret them.High-dose methylprednisolone in children with Crimean-Congo haemorrhagic fever.Person-to-person transmission of severe fever with thrombocytopenia syndrome bunyavirus through blood contactLethal Crimean-Congo hemorrhagic fever virus infection in interferon α/β receptor knockout mice is associated with high viral loads, proinflammatory responses, and coagulopathy.Efficacy of high-dose methylprednisolone in patients with Crimean-Congo haemorrhagic fever and severe thrombocytopenia.Case-fatality ratio and effectiveness of ribavirin therapy among hospitalized patients in china who had severe fever with thrombocytopenia syndrome.Clinical features and factors associated with severity and fatality among patients with severe fever with thrombocytopenia syndrome Bunyavirus infection in Northeast China.Meta-analysis of the clinical and laboratory parameters of SFTS patients in China.Virus detection and monitoring of viral load in Crimean-Congo hemorrhagic fever virus patients.Interacting roles of immune mechanisms and viral load in the pathogenesis of crimean-congo hemorrhagic fever.Determination of serum adenosine deaminase and xanthine oxidase levels in patients with crimean-congo hemorrhagic fever.Crimean-Congo hemorrhagic fever: epidemiological trends and controversies in treatmentCrimean-Congo hemorrhagic fever in Iran.Can serum ferritin level predict disease severity in patients with crimean-congo hemorrhagic Fever?Exotic emerging viral diseases: progress and challenges.Viral load as predictor of Crimean-Congo hemorrhagic fever outcome.Viral zoonoses in Europe.Evaluation of Prognostic Values of Tissue Plasminogen Activator and Plasminogen Activator Inhibitor-1 in Crimean-Congo Hemorrhagic Fever PatientsCrimean-Congo hemorrhagic fever: Risk factors and control measures for the infection abatementEpidemiologic features and risk factors of Crimean-Congo hemorrhagic fever in Samsun province, Turkey.Close contact precautions could prevent an outbreak of crimean-congo hemorrhagic Fever: a case series report from southern part of tehranCrimean congo hemorrhagic fever appearance in the north of Iran.Crimean-Congo hemorrhagic fever virus in high-risk population, Turkey.Evaluation of patients with Crimean-Congo hemorrhagic fever in Bolu, Turkey.Value of ABO blood group in predicting the severity of children with Crimean-Congo hemorrhagic fever.Current treatment of Crimean-Congo hemorrhagic fever in children.An update on crimean congo hemorrhagic FeverCrimean-Congo hemorrhagic fever: an overview.Carbonic anhydrase I-II autoantibodies and oxidative status in long-term follow-up of patients with Crimean-Congo haemorrhagic fever.Determination of nasal mucociliary clearance time and nasal symptom in patients with Crimean-Congo hemorrhagic fever.Fluorometric CCHFV OTU protease assay with potent inhibitors.
P2860
Q24599685-0BF12E88-EEFF-417F-8676-2803862A42B6Q26700150-32773682-EC86-4C74-BEC3-4D24248FFA67Q26801180-6DF39661-C414-4CD6-A67C-3E7DBFA23CDCQ26825708-F61F353E-1A66-4450-A2F1-3D68142603B0Q27477574-C8178ADC-EEE3-4B0E-815B-86F0A797E1EBQ27928040-6EB227A4-A195-45D7-BDB5-5ED8C76EF694Q28235257-7CD8A619-9FC9-4D28-8514-30519C3783DAQ33286943-E7C41561-4257-4836-9B35-9E2679DBF6F4Q33383311-5DBB6640-A4C1-418C-A1EE-9CD1F2E4FD4CQ33386900-DE4295A7-50F5-406F-BC44-4F868863012EQ33387845-BCECFEFF-C629-495D-B689-99FB19C31A57Q33398319-81B8A17D-7411-4886-AD41-B9B190C3A71DQ33405943-633120D9-3DDE-4C28-BAD3-67EFB22E7DCAQ33408612-425C225A-C565-43B9-B09C-58FF8981DD10Q33409920-70C19E42-98BB-4B02-9D47-F7A68F5A1949Q33411483-0CEA4198-CB02-4FF4-8F71-50F7F9670A50Q33437190-D69C6A8D-8B7B-4027-BCA9-615B1E5032CAQ33884110-41A0FA9D-5A04-4D47-A01D-3483669D66D0Q33962671-8ACFBCDE-F0F2-4132-94E8-F552E783AAEFQ34023473-358C1284-364A-4F70-868C-18F7603EAD73Q34094867-A5EA6257-ACB4-48B2-A444-AAE8F2784572Q34663353-2F259A15-7A3D-4E25-97DC-D0B32C227FA0Q34667085-443123B8-7ED4-4958-B58C-62BBBEDF0430Q35971398-EEE12CF2-974A-438A-9EEB-A32B0D417FF8Q36034019-AF405F88-A9A2-40F9-A195-96152EA13168Q36197670-71565C42-4005-4E2E-BF68-67AB83B7D67FQ36278624-EF0EBE80-026F-4DBD-BD80-C770CD76FF3EQ36502219-FB052D6E-5C11-4619-9659-60B25CE611E2Q36978742-74C32366-84EC-4B8E-8AEB-911283CF04C2Q37068824-82E9785F-85F5-47EC-B9C6-5D1FDBCD6A13Q37145269-52B7733B-BD73-41FA-AD07-B430D98A9BE1Q37189502-6A07FB01-F331-4E20-8D16-CCADA416578FQ37299192-A5632903-2972-4B24-9B2F-513166065046Q37597456-EB72E369-DE87-4D3E-9964-D0987A79E457Q37778828-9BB7F823-8614-4D20-A3E3-2ECC4DCEE954Q37925593-0E6C9DAA-37FF-461E-A963-7E2FE1CC6EB9Q38126427-40E856FD-4135-485D-AFCC-128FD57AE5E8Q40043832-A4071D9C-4D87-411A-805C-0D83916EDF6BQ40081192-1A8B1CFB-C446-4727-9B5A-74B143850909Q40148157-A34D6443-0C6E-4AF6-A1D1-A577B9CD157A
P2860
Characteristics of patients with Crimean-Congo hemorrhagic fever in a recent outbreak in Turkey and impact of oral ribavirin therapy
description
2004 nî lūn-bûn
@nan
2004 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
name
Characteristics of patients wi ...... pact of oral ribavirin therapy
@ast
Characteristics of patients wi ...... pact of oral ribavirin therapy
@en
Characteristics of patients wi ...... pact of oral ribavirin therapy
@nl
type
label
Characteristics of patients wi ...... pact of oral ribavirin therapy
@ast
Characteristics of patients wi ...... pact of oral ribavirin therapy
@en
Characteristics of patients wi ...... pact of oral ribavirin therapy
@nl
prefLabel
Characteristics of patients wi ...... pact of oral ribavirin therapy
@ast
Characteristics of patients wi ...... pact of oral ribavirin therapy
@en
Characteristics of patients wi ...... pact of oral ribavirin therapy
@nl
P2093
P3181
P356
P1476
Characteristics of patients wi ...... pact of oral ribavirin therapy
@en
P2093
Aysel Celikbaş
Başak Dokuzoguz
Harika Esener
Nurcan Baykam
Onder Ergönül
Sebnem Eren
P3181
P356
10.1086/422000
P407
P577
2004-07-15T00:00:00Z